eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer Portfolio News / By Karina Tin August 8, 2022 eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer Read More »
Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders Portfolio News / By Karina Tin August 5, 2022 Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders Read More »
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results Portfolio News / By Karina Tin August 4, 2022 NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results Read More »
Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer Portfolio News / By Karina Tin August 3, 2022 Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer Read More »
Carmot Therapeutics Closes $160 Million Series D Financing to Advance Clinical Pipeline of Novel Incretin Receptor Modulators Portfolio News / By Karina Tin July 26, 2022 Carmot Therapeutics Closes $160 Million Series D Financing to Advance Clinical Pipeline of Novel Incretin Receptor Modulators Read More »
Circle Pharma Appoints Paul Park MBA as CBO Portfolio News / By Karina Tin July 26, 2022 Circle Pharma Appoints Paul Park MBA as CBO Read More »
Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives Portfolio News / By Karina Tin July 21, 2022 Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives Read More »
Nurix Therapeutics Announces $40 Million Registered Direct Offering Portfolio News / By Karina Tin July 8, 2022 Nurix Therapeutics Announces $40 Million Registered Direct Offering Read More »
Nurix Therapeutics Announces $55 Million Registered Direct Offering Portfolio News / By Karina Tin July 7, 2022 Nurix Therapeutics Announces $55 Million Registered Direct Offering Read More »
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin July 7, 2022 Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update Read More »
